Alzheimer’s drugs ‘will not address dementia risk at scale’, researchers claim

Yui Mok/PA Wire

By Storm Newton, PA Media

New drugs being developed to tackle Alzheimer’s disease “will not address dementia risk at scale”, researchers have warned.

Academics said there is “a lot of hyperbole” around medications such as lecanemab and donanemab which are said to slow down early stages of Alzheimer’s.